← Back to Search

Wearable Biosensors for Autoimmune Epilepsy

N/A
Waitlist Available
Led By Benjamin Brinkmann, PhD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients diagnosed with or suspected of having autoimmune epilepsy
Normal controls - cognitively normal subjects without epilepsy
Must not have
Presence of open or healing wounds near monitoring sites (infection risk)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 days
Awards & highlights
No Placebo-Only Group

Summary

This trial seeks to detect physical signals that can help predict epileptic seizures, such as heart rate, muscle activity and EEG.

Who is the study for?
This trial is for individuals diagnosed with or suspected to have autoimmune epilepsy, as well as healthy people without epilepsy. Participants must be able to manage smart devices and not have open wounds near monitoring sites or cognitive conditions that would limit cooperation.
What is being tested?
The study is testing wearable biosensors on patients with autoimmune epilepsy and healthy subjects. It aims to identify consistent changes in physical signals like heart rate, muscle activity, and brain waves before and during seizures.
What are the potential side effects?
Since the intervention involves non-invasive wearable devices, side effects are minimal but may include discomfort from wearing the device or skin irritation at the site of wear.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with or suspected to have autoimmune epilepsy.
Select...
I do not have epilepsy and my cognitive functions are normal.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have open or healing wounds near areas that would be monitored.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Reproducible changes in physiological biosignals
Number of high-quality physiological signals

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Autoimmune Epilepsy with BiosensorsExperimental Treatment1 Intervention
Subjects with suspected autoimmune epilepsy will wear biosensors on wrist or upper arm during the at home monitoring period.
Group II: Healthy Controls with BiosensorsActive Control1 Intervention
Neurologically normal adult healthy controls will wear biosensors on wrist or upper arm during the at home monitoring period.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,326 Previous Clinical Trials
3,059,442 Total Patients Enrolled
1 Trials studying Autoimmune Epilepsy
17 Patients Enrolled for Autoimmune Epilepsy
Benjamin Brinkmann, PhDPrincipal InvestigatorMayo Clinic

Media Library

Autoimmune Epilepsy with Biosensors Clinical Trial Eligibility Overview. Trial Name: NCT05627661 — N/A
Autoimmune Epilepsy Research Study Groups: Healthy Controls with Biosensors, Autoimmune Epilepsy with Biosensors
Autoimmune Epilepsy Clinical Trial 2023: Autoimmune Epilepsy with Biosensors Highlights & Side Effects. Trial Name: NCT05627661 — N/A
Autoimmune Epilepsy with Biosensors 2023 Treatment Timeline for Medical Study. Trial Name: NCT05627661 — N/A
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top